{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:08:36Z","timestamp":1790615316790,"version":"4.1.0"},"reference-count":227,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002567","name":"American Academy of Allergy Asthma and Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jaci.2019.08.023","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:20:23Z","timestamp":1567192823000},"page":"883-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management"],"prefix":"10.1016","volume":"144","author":[{"given":"Catherine R.","family":"Weiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Frank","family":"Austen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla S.","family":"Barkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanai","family":"Pongdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Shahzad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harissios","family":"Vliagoftis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.08.023_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib3","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clinthera.2013.04.001","article-title":"Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes","volume":"35","author":"Picard","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2019.08.023_bib8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib9","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2014.06.007","article-title":"Familial hypertryptasemia with associated mast cell activation syndrome","volume":"134","author":"Sabato","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib11","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaci.2019.08.023_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.clinbiochem.2016.02.007","article-title":"Analytical and clinical validation of an LC-MS\/MS method for urine leukotriene E4: a marker of systemic mastocytosis","volume":"49","author":"Lueke","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaci.2019.08.023_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.12128","article-title":"Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis","volume":"91","author":"Kristensen","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib15","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.08.023_bib16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3109\/10428194.2012.763121","article-title":"Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis","volume":"54","author":"Quintas-Cardama","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2019.08.023_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cccn.2005.03.041","article-title":"Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis","volume":"359","author":"van Toorenenbergen","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaci.2019.08.023_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000048184","article-title":"Surrogate markers of disease in mastocytosis","volume":"127","author":"Akin","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1046\/j.1365-2230.2002.01072.x","article-title":"Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis","volume":"27","author":"Oranje","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators\u00a0of indolent systemic mastocytosis without skin lesions","volume":"67","author":"van Doormaal","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/1523-1747.ep12606209","article-title":"Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2","volume":"104","author":"Morrow","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.20452\/pamw.1379","article-title":"Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4","volume":"122","author":"Celejewska-Wojcik","year":"2012","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.jaci.2019.08.023_bib24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib25","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gim.2017.136","article-title":"A common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number","volume":"20","author":"Lyons","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib27","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2019.08.023_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2019.08.023_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","article-title":"Nonclonal mast cell activation syndrome: a growing body of evidence","volume":"38","author":"Hamilton","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib34","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaci.2019.08.023_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaip.2014.03.007","article-title":"Mast cell activation disorders","volume":"2","author":"Akin","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease\u2014a guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaci.2019.08.023_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2016.01.003","article-title":"Mast cell activation disease and the modern epidemic of chronic inflammatory disease","volume":"174","author":"Afrin","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2019.08.023_bib40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2010.12.1113","article-title":"Interdisciplinary Multicenter Research Group on Systemic Mast Cell Activation Disease. Toward a global classification of mast cell activation diseases","volume":"127","author":"Molderings","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2016.03.003","article-title":"A new era for an old cell: heightened appreciation of mast cell disease emerges","volume":"174","author":"Afrin","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib44","first-page":"61","article-title":"[Severe mast cell activation syndrome in a 15-year-old patient with an hypermobile Ehlers-Danlos syndrome]","volume":"73","author":"Daens","year":"2018","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.jaci.2019.08.023_bib45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajmg.c.31555","article-title":"Mast cell disorders in Ehlers-Danlos syndrome","volume":"175","author":"Seneviratne","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.jaci.2019.08.023_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.iac.2018.04.004","article-title":"Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders","volume":"38","author":"Bonamichi-Santos","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11910-015-0583-8","article-title":"Postural tachycardia syndrome: beyond orthostatic intolerance","volume":"15","author":"Garland","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jaci.2019.08.023_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.autneu.2018.04.004","article-title":"Evaluation of postural tachycardia syndrome (POTS)","volume":"215","author":"Goodman","year":"2018","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.jaci.2019.08.023_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.prp.2011.12.005","article-title":"Sclerosing mediastinitis and mast cell activation syndrome","volume":"208","author":"Afrin","year":"2012","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MAJ.0b013e31821d41dd","article-title":"Polycythemia from mast cell activation syndrome: lessons learned","volume":"342","author":"Afrin","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaci.2019.08.023_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7205\/MILMED-D-11-00111","article-title":"Mast cell activation syndrome masquerading as agranulocytosis","volume":"177","author":"Afrin","year":"2012","journal-title":"Mil Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MAJ.0000000000000325","article-title":"Mast cell activation syndrome as a significant comorbidity in sickle cell disease","volume":"348","author":"Afrin","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaci.2019.08.023_bib53","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1160\/TH11-05-0351","article-title":"Bleeding diathesis in patients with mast cell activation disease","volume":"106","author":"Seidel","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaci.2019.08.023_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tripleo.2010.11.030","article-title":"Burning mouth syndrome and mast cell activation disorder","volume":"111","author":"Afrin","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaci.2019.08.023_bib55","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","article-title":"Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases","volume":"50","author":"Afrin","year":"2015","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jaci.2019.08.023_bib56","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s10803-010-1171-z","article-title":"Brief report: \u201callergic symptoms\u201d in children with Autism Spectrum Disorders. More than meets the eye?","volume":"41","author":"Angelidou","year":"2011","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.jaci.2019.08.023_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41398-018-0143-5","article-title":"White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome","volume":"8","author":"Haenisch","year":"2018","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jaci.2019.08.023_bib58","first-page":"129","article-title":"Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome","volume":"28","author":"Afrin","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jaci.2019.08.023_bib59","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clbc.2017.12.004","article-title":"Mast cell activation syndrome mimicking breast cancer: case report with pathophysiologic considerations","volume":"18","author":"Molderings","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jaci.2019.08.023_bib60","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.12688\/f1000research.12730.1","article-title":"Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA","volume":"6","author":"Molderings","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2162-3619-2-28","article-title":"Utility of hydroxyurea in mast cell activation syndrome","volume":"2","author":"Afrin","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jaci.2019.08.023_bib62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ejh.12606","article-title":"Successful treatment of mast cell activation syndrome with sunitinib","volume":"95","author":"Afrin","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12893","article-title":"Successful targeted treatment of mast cell activation syndrome with tofacitinib","volume":"99","author":"Afrin","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2500\/108854194778816472","article-title":"Human mast cell heterogeneity","volume":"15","author":"Irani","year":"1994","journal-title":"Allergy Proc"},{"key":"10.1016\/j.jaci.2019.08.023_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02904705","article-title":"Histidine decarboxylase in peripheral lymphocytes of healthy individuals and chronic lymphoid leukemia patients","volume":"4","author":"Bencsath","year":"1998","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib66","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1096\/fj.12-223867","article-title":"Histamine production by human neutrophils","volume":"27","author":"Alcaniz","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2019.08.023_bib67","doi-asserted-by":"crossref","first-page":"29011","DOI":"10.1074\/jbc.M501164200","article-title":"A novel\u00a0pathophysiological mechanism for osteoporosis suggested by an in\u00a0vivo\u00a0gene expression study of circulating monocytes","volume":"280","author":"Liu","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2019.08.023_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5551\/jat.11.122","article-title":"Role of macrophage-derived histamine in atherosclerosis\u2014chronic participation in the inflammatory response","volume":"11","author":"Sasaguri","year":"2004","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jaci.2019.08.023_bib69","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjd.14995","article-title":"Histamine metabolism and transport are deranged in human keratinocytes in oral lichen planus","volume":"176","author":"Salem","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2010.256","article-title":"Histamine: new thoughts about a familiar mediator","volume":"89","author":"Jones","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2019.08.023_bib71","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaci.2011.06.051","article-title":"Regulation of the immune response and inflammation by histamine and histamine receptors","volume":"128","author":"O'Mahony","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib72","doi-asserted-by":"crossref","first-page":"e31951","DOI":"10.1371\/journal.pone.0031951","article-title":"Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling","volume":"7","author":"Thomas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.08.023_bib73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2015.05.038","article-title":"Histamine induced coronary artery spasm, fish consumption and Kounis syndrome","volume":"193","author":"Kounis","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaci.2019.08.023_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12016-015-8467-x","article-title":"Histamine (scombroid) fish poisoning: a comprehensive review","volume":"50","author":"Feng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/17843286.2016.1265756","article-title":"Kounis syndrome following canned tuna fish ingestion","volume":"72","author":"De Gennaro","year":"2017","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaci.2019.08.023_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15563650.2017.1349320","article-title":"Histamine poisoning from insect consumption: an outbreak investigation from Thailand","volume":"56","author":"Chomchai","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaci.2019.08.023_bib77","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/ACI.0000000000000297","article-title":"Scombroid syndrome: it seems to be fish allergy but\u2026 it isn't","volume":"16","author":"Ridolo","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib78","doi-asserted-by":"crossref","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.08.023_bib79","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/leu.2013.227","article-title":"Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2019.08.023_bib80","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib81","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2008.01.019","article-title":"Chimerism, point mutation, and truncation dramatically transformed mast cell delta-tryptases during primate evolution","volume":"121","author":"Trivedi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib82","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2009.07.026","article-title":"Human subjects are\u00a0protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations","volume":"124","author":"Trivedi","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1165\/rcmb.2009-0324RT","article-title":"Mast cell peptidases: chameleons of innate immunity and host defense","volume":"42","author":"Trivedi","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2019.08.023_bib84","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.179.9.6072","article-title":"Mast cell alpha and beta tryptases changed rapidly during primate speciation and evolved from gamma-like transmembrane peptidases in ancestral vertebrates","volume":"179","author":"Trivedi","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib85","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib86","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib87","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2004.02.032","article-title":"Expression of alpha-tryptase and beta-tryptase by human basophils","volume":"113","author":"Jogie-Brahim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib88","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.4049\/jimmunol.138.8.2611","article-title":"Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells","volume":"138","author":"Schwartz","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(06)80017-5","article-title":"Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation","volume":"90","author":"Van der Linden","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib90","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0091-6749(87)80276-2","article-title":"Release of tryptase together with histamine during the immediate cutaneous response to allergen","volume":"80","author":"Schwartz","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib91","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic-anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib92","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI114051","article-title":"Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis","volume":"83","author":"Schwartz","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2019.08.023_bib93","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2015.09.001","article-title":"Tryptase levels in children presenting with anaphylaxis: temporal trends and associated factors","volume":"137","author":"De Schryver","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib94","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/all.13752","article-title":"Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study 97\/100","volume":"74","author":"Vitte","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib95","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2015.07.001","article-title":"Serum levels of 9\u03b1,11\u03b2-PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis","volume":"137","author":"Nassiri","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib97","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.aller.2014.05.002","article-title":"Clinical characteristics and risk profile of patients with elevated baseline serum tryptase","volume":"42","author":"Fellinger","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2019.08.023_bib98","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2500\/aap.2014.35.3769","article-title":"Serum basal tryptase levels in healthy children: correlation between age and gender","volume":"35","author":"Sahiner","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2019.08.023_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ajd.12146","article-title":"Disease spectrum in patients with elevated serum tryptase levels","volume":"56","author":"Aberer","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2222.2009.03436.x","article-title":"Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy","volume":"40","author":"Dugas-Breit","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib101","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jaci.2013.03.028","article-title":"Serum tryptase determination in patients with acute allergic reactions","volume":"131","author":"Vitte","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib102","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2014.04.001","article-title":"Human mast cell tryptase in biology and medicine","volume":"63","author":"Vitte","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-4838(00)00161-8","article-title":"Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase","volume":"1482","author":"Urade","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2019.08.023_bib104","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.RES.86.9.967","article-title":"Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase expression in vascular endothelial cells","volume":"86","author":"Taba","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/JBMR.041211","article-title":"Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors","volume":"20","author":"Gallant","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib106","doi-asserted-by":"crossref","first-page":"28263","DOI":"10.1074\/jbc.272.45.28263","article-title":"Prostaglandin D synthase in human megakaryoblastic cells","volume":"272","author":"Mahmud","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2019.08.023_bib107","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.jnen.0000240472.43038.27","article-title":"Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease","volume":"66","author":"Mohri","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jaci.2019.08.023_bib108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2353\/ajpath.2010.090111","article-title":"Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin","volume":"176","author":"Shimura","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2019.08.023_bib109","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.4049\/jimmunol.1101806","article-title":"Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation","volume":"187","author":"Luna-Gomes","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib110","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.164.5.2277","article-title":"Cutting edge: differential production of prostaglandin D-2 by human helper T cell subsets","volume":"164","author":"Tanaka","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0952-3278(91)90138-U","article-title":"Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects","volume":"44","author":"Van der Donk","year":"1991","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jaci.2019.08.023_bib112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1476-5381.1987.tb11366.x","article-title":"Prostaglandin D2 release from human skin mast cells in response to ionophore A23187","volume":"92","author":"Benyon","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2019.08.023_bib113","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0090-6980(85)90114-5","article-title":"Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosis","volume":"30","author":"Roberts","year":"1985","journal-title":"Prostaglandins"},{"key":"10.1016\/j.jaci.2019.08.023_bib114","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00005-015-0334-1","article-title":"9\u03b1,11\u03b2-PGF2, a prostaglandin D2 metabolite, as a marker of mast cell activation in bee venom-allergic patients","volume":"63","author":"Nittner-Marszalska","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jaci.2019.08.023_bib116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0022-202X(89)90066-3","article-title":"The IgE- and calcium-dependent release of eicosanoids and histamine from human purified cutaneous mast cells","volume":"93","author":"Robinson","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib117","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1476-5381.1989.tb12030.x","article-title":"Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli","volume":"97","author":"Benyon","year":"1989","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2019.08.023_bib118","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1164\/ajrccm\/141.4_Pt_1.960","article-title":"Disassociation of the release of histamine and arachidonic acid metabolites from osmotically activated basophils and human lung mast cells","volume":"141","author":"Eggleston","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaci.2019.08.023_bib119","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1016\/S0021-9258(18)51570-2","article-title":"The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils","volume":"264","author":"Lam","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2019.08.023_bib120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02737601","article-title":"LTC4 synthase. Enzymology, biochemistry, and molecular characterization","volume":"17","author":"Penrose","year":"1999","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib121","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.iac.2007.09.004","article-title":"Urinary leukotriene E4","volume":"27","author":"Rabinovitch","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib122","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib123","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","article-title":"Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib124","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib125","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib126","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2745.2002.01501.x","article-title":"The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions","volume":"32","author":"Berges-Gimeno","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib127","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib128","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib129","first-page":"540","article-title":"Metrorrhagia as an uncommon symptom of anaphylaxis","volume":"20","author":"Gonzalo-Garijo","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib130","doi-asserted-by":"crossref","first-page":"e1414","DOI":"10.1097\/MD.0000000000001414","article-title":"A French National Survey on clotting disorders in mastocytosis","volume":"94","author":"Carvalhosa","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2019.08.023_bib131","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A\u00a0as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jaci.2019.08.023_bib132","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2017.08.022","article-title":"Chromogranin A\u00a0is not a biomarker of mastocytosis","volume":"6","author":"Hanjra","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib133","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF01965099","article-title":"Concentration effect relationships of infused histamine in normal volunteers","volume":"12","author":"Ind","year":"1982","journal-title":"Agents Actions"},{"key":"10.1016\/j.jaci.2019.08.023_bib134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jpba.2015.11.001","article-title":"Comparison of two enzymatic immunoassays, high resolution mass spectrometry method and radioimmunoassay for the quantification of human plasma histamine","volume":"118","author":"Poli","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jaci.2019.08.023_bib135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0003-2697(84)90037-X","article-title":"Measurement of plasma histamine by stable isotope dilution gas chromatography-mass spectrometry: methodology and normal values","volume":"139","author":"Keyzer","year":"1984","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jaci.2019.08.023_bib136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","article-title":"Drug-induced cognitive impairment in the elderly","volume":"15","author":"Moore","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jaci.2019.08.023_bib137","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1532-5415.2007.01270.x","article-title":"The association between cognition and histamine-2 receptor antagonists in African Americans","volume":"55","author":"Boustani","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jaci.2019.08.023_bib138","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2019.08.023_bib139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ggi.13032","article-title":"Association between using medications with anticholinergic properties and short-term cognitive decline among older men: a retrospective cohort study in Taiwan","volume":"17","author":"Wu","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jaci.2019.08.023_bib140","doi-asserted-by":"crossref","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2019.08.023_bib141","first-page":"639","article-title":"A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs","volume":"29","author":"Tannenbaum","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jaci.2019.08.023_bib142","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib143","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis\u2014a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib144","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11882-015-0550-0","article-title":"Hymenoptera anaphylaxis and C-kit mutations: an unexpected association","volume":"15","author":"Bonadonna","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2019.08.023_bib145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaip.2013.10.002","article-title":"Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria","volume":"2","author":"Rajan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib146","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations","volume":"12","author":"Castells","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib147","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ACI.0000000000000377","article-title":"Pharmacotherapy of mast cell disorders","volume":"17","author":"Gulen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib148","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/ACI.0000000000000071","article-title":"Anaphylaxis and cardiovascular diseases: a dangerous liaison","volume":"14","author":"Triggiani","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib149","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0091-6749(90)90205-I","article-title":"Ketotifen and systemic mastocytosis","volume":"85","author":"Ting","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/all.12159","article-title":"Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Siebenhaar","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib151","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/all.12672","article-title":"H1-antihistamines for primary mast cell activation syndromes: a systematic review","volume":"70","author":"Nurmatov","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib152","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","article-title":"Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis","volume":"90","author":"Hirschowitz","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib153","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0091-6749(81)90134-2","article-title":"Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses","volume":"68","author":"Kaliner","year":"1981","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib154","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1021\/acs.jmedchem.7b01855","article-title":"Discovery of a novel highly selective histamine H4 receptor antagonist for the treatment of atopic dermatitis","volume":"61","author":"Ko","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2019.08.023_bib155","first-page":"145","article-title":"Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks","volume":"8","author":"Roberts","year":"1982","journal-title":"Adv Shock Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib156","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(89)91516-X","article-title":"Aspirin and systemic mastocytosis","volume":"2","author":"Lorcerie","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2019.08.023_bib157","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2019.08.023_bib158","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib159","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib160","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0190-9622(83)70140-4","article-title":"Treatment of bullous mastocytosis with disodium cromoglycate","volume":"9","author":"Welch","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib162","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","article-title":"Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?","volume":"3","author":"Castells","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib163","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"da Silva","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib164","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jaci.2007.05.034","article-title":"Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding","volume":"120","author":"Klunker","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib166","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","article-title":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","volume":"108","author":"Bell","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib167","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib168","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib169","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.08.023_bib170","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib171","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib172","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib173","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib174","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2019.08.023_bib175","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib177","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2019.08.023_bib178","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2019.08.023_bib179","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib180","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaci.2019.08.023_bib181","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib182","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2019.08.023_bib183","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib184","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11899-018-0469-3","article-title":"Clinical validation of KIT inhibition in advanced systemic mastocytosis","volume":"13","author":"Baird","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jaci.2019.08.023_bib186","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0000000000000486","article-title":"Novel approaches for systemic mastocytosis","volume":"26","author":"Fletcher","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib187","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib188","doi-asserted-by":"crossref","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib189","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib191","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib192","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.08.023_bib193","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","article-title":"Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature","volume":"17","author":"Pardanani","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib194","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01407.x","article-title":"A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions","volume":"84","author":"Pardanani","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro)endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaci.2019.08.023_bib196","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaad.2005.07.057","article-title":"The flushing patient: differential diagnosis, workup, and treatment","volume":"55","author":"Izikson","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib197","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.12.032","article-title":"Etiologies and management of cutaneous flushing: malignant causes","volume":"77","author":"Sadeghian","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib198","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2016.12.031","article-title":"Etiologies and management of cutaneous flushing: nonmalignant causes","volume":"77","author":"adeghian","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib199","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/0003-4819-95-4-468","article-title":"Flushing reactions: consequences and mechanisms","volume":"95","author":"Wilkin","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-4362.1985.tb05847.x","article-title":"The flushing patient","volume":"24","author":"Mooney","year":"1985","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clindermatol.2014.02.019","article-title":"Red face revisited: flushing","volume":"32","author":"Ikizoglu","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.clindermatol.2014.02.011","article-title":"Red face and fungi infection","volume":"32","author":"Welsh","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib203","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/EJE-17-0295","article-title":"Management of endocrine disease: flushing: current concepts","volume":"177","author":"Huguet","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaci.2019.08.023_bib204","first-page":"1319","article-title":"Management of hot flushes due to endocrine therapy for prostate carcinoma","volume":"10","author":"Smith","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.jaci.2019.08.023_bib205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0738-081X(96)00116-2","article-title":"Dermatologic problems of the menopause","volume":"15","author":"Graham-Brown","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib206","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0045(2000)45:10+<32::AID-PROS7>3.0.CO;2-V","article-title":"Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens","volume":"10","author":"Hedlund","year":"2000","journal-title":"Prostate Suppl"},{"key":"10.1016\/j.jaci.2019.08.023_bib207","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0889-8529(18)30136-1","article-title":"The pathology of the gastrointestinal endocrine system","volume":"22","author":"Solcia","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jaci.2019.08.023_bib208","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0344-0338(11)80890-3","article-title":"Endocrine tumors of the small and large intestine","volume":"191","author":"Solcia","year":"1995","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaci.2019.08.023_bib209","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0950-3528(96)90015-9","article-title":"Carcinoid tumours","volume":"10","author":"Tiensuu Janson","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"10.1016\/j.jaci.2019.08.023_bib210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11864-002-0031-2","article-title":"Carcinoid tumors","volume":"3","author":"Boushey","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jaci.2019.08.023_bib211","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaad.2006.07.008","article-title":"Flushing, pheochromocytoma, and the dermatologist","volume":"55","author":"Heymann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.08.023_bib212","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical syndromes related to gastrointestinal neuroendocrine neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"key":"10.1016\/j.jaci.2019.08.023_bib213","first-page":"253","article-title":"Adverse effects of sustained-release niacin","volume":"25","author":"Knapp","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.jaci.2019.08.023_bib214","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/PPA.S56002","article-title":"A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil","volume":"9","author":"Evans","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaci.2019.08.023_bib215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0098-2997(88)90019-2","article-title":"Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcoholic liver disease","volume":"10","author":"Bosron","year":"1988","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.jaci.2019.08.023_bib216","first-page":"55","article-title":"Vasoactive intestinal peptide secreting tumours in children: a case report with literature review","volume":"24","author":"Quak","year":"1988","journal-title":"Aust Paediatr J"},{"key":"10.1016\/j.jaci.2019.08.023_bib217","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01952307.1992.11735871","article-title":"Autonomic hyperreflexia with spinal cord injury","volume":"15","author":"Colachis","year":"1992","journal-title":"J Am Paraplegia Soc"},{"key":"10.1016\/j.jaci.2019.08.023_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2007.05.004","article-title":"Unnoticed dysautonomic syndrome of the face: Harlequin syndrome","volume":"137","author":"Tascilar","year":"2007","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.jaci.2019.08.023_bib219","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2019.08.023_bib220","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2353\/jmoldx.2006.060089","article-title":"Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia","volume":"8","author":"Corless","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jaci.2019.08.023_bib221","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib222","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jaci.2019.08.023_bib223","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jcp.2007.047928","article-title":"Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR","volume":"61","author":"Schumacher","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaci.2019.08.023_bib224","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/17843286.2017.1293312","article-title":"Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients","volume":"72","author":"Van den Poel","year":"2017","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaci.2019.08.023_bib225","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/bjh.15624","article-title":"Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease","volume":"183","author":"Carter","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2019.08.023_bib226","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.08.023_bib227","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919311169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919311169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:21:30Z","timestamp":1758792090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919311169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":227,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0091674919311169"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.08.023","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}